ZURA - NASDAQ

Zura Bio Limited

ZURA·NASDAQ

$3.86

-5.9%

HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$250.98M

EPS-1.0600

P/E Ratio-3.64

Earnings Date08/13/2026

zura

Cash at End of Period

Last Annual Value

109.41M

3-Year CAGR

312%

5-Year CAGR

172%

10-Year CAGR

65%

Adjust for Inflation

Zura Bio Limited Competitors Analysis of Cash at End of Period

ZURA · NASDAQ

Company	Cash at End of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
Zura Bio Limited NASDAQ:ZURA	109.41M	3.1%	172.4%	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	16.89M	14.9%	-42.8%	N/A
Caribou Biosciences, Inc. NASDAQ:CRBU	12.41M	-37.7%	-44.7%	N/A
Neonc Technologies Holdings, Inc. NASDAQ:NTHI	58.73K	22.6%	18.6%	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	71.89M	201.2%	27.4%	14.8%
Entrada Therapeutics, Inc. NASDAQ:TRDA	94.34M	9.7%	-20.2%	N/A
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD	47.05M	69.1%	N/A	N/A
Immuneering Corporation NASDAQ:IMRX	128.65M	29.4%	11.4%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	100.97M	29.6%	21.2%	N/A
Sagimet Biosciences Inc. NASDAQ:SGMT	35.02M	-22.5%	-9.2%	N/A
Assembly Biosciences, Inc. NASDAQ:ASMB	58.45M	43.4%	5.1%	7.4%

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.86, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

HIDDEN

Intrinsic Value

Current Price: $3.86

Related Guides

Blog Categories

Continue your ZURA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.